Mind Medicine ($MNMD) Doses First Patient in Phase 2b Trial to Treat Generalized Anxiety Disorder
Mind Medicine (MNMD), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, has announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a...
Read More